Literature DB >> 14962252

Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma.

Kazuki Koizumi1, Katsuya Fujimoto, Yoshihito Haseyama, Tomoyuki Endo, Mitsufumi Nishio, Kouichi Yokota, Tomoo Itoh, Ken-ichi Sawada, Takao Koike.   

Abstract

The prognosis of nasal natural killer (NK)/T-cell lymphoma with cutaneous involvement especially is morbid despite intensive chemotherapy and radiotherapy. We treated a 52-yr-old Japanese woman with cutaneous dissemination of nasal NK/T-cell lymphoma. Six cycles of chemotherapy, irradiation to skin lesion were administered and complete remission (CR) was attained. High-dose chemotherapy (HDC; etoposide 750 mg/m(2) x 2 d, cyclophosphamide 60 mg/kg x 2 d, total body irradiation 12 Gy two daily fractions x 3 d) followed by CD34(+)-selected autologous peripheral blood stem cell transplantation (CD34(+)-APBSCT) was then prescribed. Complete remission (CR) was obtained and she has been free of disease for 34 months since CD34(+)-APBSCT. We suggest that marrow-ablative chemotherapy facilitated by autologous stem cell transplantation should be considered part of the primary therapy for subjects with a poor prognosis for nasal NK/T-cell lymphoma with cutaneous involvement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962252     DOI: 10.1046/j.0902-4441.2003.00170.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  A case report of primary cutaneous natural killer/T-cell lymphoma.

Authors:  Chen Tian; Yong Yu; Yizhuo Zhang
Journal:  Mol Clin Oncol       Date:  2016-10-04

Review 2.  Hematopoietic stem cell transplantation in natural killer cell lymphoma and leukemia.

Authors:  Yok-Lam Kwong
Journal:  Int J Hematol       Date:  2010-11-25       Impact factor: 2.490

3.  Allogeneic haematopoietic stem cell transplantation as a salvage strategy for relapsed or refractory nasal NK/T-cell lymphoma.

Authors:  Meng Li; Chunji Gao; Honghua Li; Zhihong Wang; Yongbin Cao; Wenrong Huang; Xiaohong Li; Shuhong Wang; Li Yu; Wanming Da
Journal:  Med Oncol       Date:  2010-04-23       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.